Safety & Side Effects
CagriSema's side-effect profile looks a lot like the GLP-1 class it builds on: gastrointestinal events dominate, are do…
Mostly the gut, with class warnings to watch
CagriSema's side-effect profile looks a lot like the GLP-1 class it builds on: gastrointestinal events dominate, are dose-dependent, and drive most discontinuations. Layered on top are the class warnings (pancreatitis, gallbladder, thyroid) and a few theoretical amylin-specific concerns.
This unit separates the common-and-manageable from the serious-but-rare from the theoretical, and is honest that the long-term safety record simply does not exist yet.
Key terms
The gut side effects
The overwhelming majority of CagriSema side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. They are dose-dependent, worst during dose escalation, and the main reason people stop the drug. This profile is qualitatively the same as GLP-1 drugs, made slightly more prominent because amylin also slows the stomach.
The reassuring part is that these effects are manageable and mostly transient: slow titration, smaller low-fat meals, and hydration blunt them, and they typically ease once the maintenance dose is reached. The unreassuring part is that they still drive a meaningful discontinuation rate, so tolerability, not just efficacy, decides who stays on the drug.
AdvancedWhy adding amylin can add GI burden
Both GLP-1 and amylin slow gastric emptying, so combining them can intensify the fullness-and-nausea effect that already limits GLP-1 tolerability. This is the flip side of the additive-benefit story: the mechanisms that add weight loss also partly add side effects. It is why CagriSema's discontinuation rate is in the same range as other incretin-class agents rather than dramatically lower.